Imunon, Inc. Files 8-K: Officer/Director Changes & Compensation
Ticker: IMNN · Form: 8-K · Filed: Oct 7, 2024 · CIK: 749647
Sentiment: neutral
Topics: management-change, filing, compensation
TL;DR
Imunon's 8-K drops: new execs, director changes, and pay details filed Oct 7.
AI Summary
Imunon, Inc. filed an 8-K on October 7, 2024, reporting events as of October 2, 2024. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. It also includes Regulation FD disclosures and financial statements/exhibits.
Why It Matters
This 8-K filing indicates potential shifts in Imunon's leadership and executive compensation structures, which could signal strategic changes or governance updates.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with compensatory arrangements, can introduce uncertainty and signal strategic shifts that may impact the company's future performance.
Key Players & Entities
- Imunon, Inc. (company) — Registrant
- October 2, 2024 (date) — Earliest event reported
- October 7, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 001-15911 (filing_number) — SEC File Number
FAQ
What specific officer or director positions were affected by the events reported in this 8-K?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers', but does not specify the names or exact roles affected within this summary.
When were the events reported in this 8-K officially dated?
The earliest event reported in this 8-K filing is dated October 2, 2024.
What is Imunon, Inc.'s state of incorporation?
Imunon, Inc. is incorporated in Delaware.
What is the SEC file number for Imunon, Inc.?
The SEC file number for Imunon, Inc. is 001-15911.
Besides leadership changes, what other items are covered in this 8-K filing?
This 8-K filing also includes disclosures related to Regulation FD and financial statements and exhibits.
Filing Stats: 1,092 words · 4 min read · ~4 pages · Grade level 11.1 · Accepted 2024-10-07 08:10:19
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share IMNN Nasdaq Capital Mark
- $340,000 — ll pay Ms. Eylward an initial salary of $340,000 and Ms. Eylward will be eligible to rec
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex10-1.htm (EX-10.1) — 1KB
- ex99-1.htm (EX-99.1) — 13KB
- ex10-1_001.jpg (GRAPHIC) — 357KB
- ex10-1_002.jpg (GRAPHIC) — 228KB
- ex99-1_001.jpg (GRAPHIC) — 63KB
- 0001493152-24-039646.txt ( ) — 1131KB
- imnn-20241002.xsd (EX-101.SCH) — 3KB
- imnn-20241002_lab.xml (EX-101.LAB) — 33KB
- imnn-20241002_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Offer Letter of Employment, dated October 2, 2024, between Imunon, Inc. and Susan Eylward 99.1 Press Release of Imunon, Inc., dated October 7, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMUNON, INC. Dated: October 7, 2024 By: /s/ David Gaiero David Gaiero Chief Financial Officer